Disseminated herpes zoster in the immunocompromised host

A comparative trial of acyclovir and vidarabine

Richard J. Whitley, John W. Gnann, Daniel Hinthorn, Chein Liu, Richard B Pollard, Frederick Hayden, Gregory J. Mertz, Michael Oxman, Seng Jaw Soong

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Seventy-three immunocompromised patients with disseminated herpes zoster were evaluated in a double-blind controlled trial of acyclovir (n = 37) versus vidarabine (n = 36) therapy. Acyclovir was administered at 30 mg/kg/day at 8-h intervals and vidarabine was given as a continuous 12-h infusion at 10 mg/kg/day for 7 days (longer if resolution of cutaneous or visceral disease was incomplete). No demographic differences existed between treatment groups. No deaths attributable to varicella-zoster virus infection occurred within 1 month of treatment. Neither rates of cutaneous healing, resolution of acute neuritis, and frequency of postherpetic neuralgia nor adverse clinical and laboratory events differed between treatment groups. Acyclovir recipients were discharged from the hospital more promptly than vidarabine recipients (P = .04, log rank test). These data indicate that disseminated herpes zoster is amenable to therapy with either acyclovir or vidarabine; resultant mortality is low.

Original languageEnglish (US)
Pages (from-to)450-455
Number of pages6
JournalJournal of Infectious Diseases
Volume165
Issue number3
StatePublished - Mar 1992
Externally publishedYes

Fingerprint

Vidarabine
Acyclovir
Herpes Zoster
Immunocompromised Host
Postherpetic Neuralgia
Therapeutics
Neuritis
Skin
Human Herpesvirus 3
Virus Diseases
Demography
Mortality

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Whitley, R. J., Gnann, J. W., Hinthorn, D., Liu, C., Pollard, R. B., Hayden, F., ... Soong, S. J. (1992). Disseminated herpes zoster in the immunocompromised host: A comparative trial of acyclovir and vidarabine. Journal of Infectious Diseases, 165(3), 450-455.

Disseminated herpes zoster in the immunocompromised host : A comparative trial of acyclovir and vidarabine. / Whitley, Richard J.; Gnann, John W.; Hinthorn, Daniel; Liu, Chein; Pollard, Richard B; Hayden, Frederick; Mertz, Gregory J.; Oxman, Michael; Soong, Seng Jaw.

In: Journal of Infectious Diseases, Vol. 165, No. 3, 03.1992, p. 450-455.

Research output: Contribution to journalArticle

Whitley, RJ, Gnann, JW, Hinthorn, D, Liu, C, Pollard, RB, Hayden, F, Mertz, GJ, Oxman, M & Soong, SJ 1992, 'Disseminated herpes zoster in the immunocompromised host: A comparative trial of acyclovir and vidarabine', Journal of Infectious Diseases, vol. 165, no. 3, pp. 450-455.
Whitley, Richard J. ; Gnann, John W. ; Hinthorn, Daniel ; Liu, Chein ; Pollard, Richard B ; Hayden, Frederick ; Mertz, Gregory J. ; Oxman, Michael ; Soong, Seng Jaw. / Disseminated herpes zoster in the immunocompromised host : A comparative trial of acyclovir and vidarabine. In: Journal of Infectious Diseases. 1992 ; Vol. 165, No. 3. pp. 450-455.
@article{a18b9666034b4fc89f962dbf2b63eeb0,
title = "Disseminated herpes zoster in the immunocompromised host: A comparative trial of acyclovir and vidarabine",
abstract = "Seventy-three immunocompromised patients with disseminated herpes zoster were evaluated in a double-blind controlled trial of acyclovir (n = 37) versus vidarabine (n = 36) therapy. Acyclovir was administered at 30 mg/kg/day at 8-h intervals and vidarabine was given as a continuous 12-h infusion at 10 mg/kg/day for 7 days (longer if resolution of cutaneous or visceral disease was incomplete). No demographic differences existed between treatment groups. No deaths attributable to varicella-zoster virus infection occurred within 1 month of treatment. Neither rates of cutaneous healing, resolution of acute neuritis, and frequency of postherpetic neuralgia nor adverse clinical and laboratory events differed between treatment groups. Acyclovir recipients were discharged from the hospital more promptly than vidarabine recipients (P = .04, log rank test). These data indicate that disseminated herpes zoster is amenable to therapy with either acyclovir or vidarabine; resultant mortality is low.",
author = "Whitley, {Richard J.} and Gnann, {John W.} and Daniel Hinthorn and Chein Liu and Pollard, {Richard B} and Frederick Hayden and Mertz, {Gregory J.} and Michael Oxman and Soong, {Seng Jaw}",
year = "1992",
month = "3",
language = "English (US)",
volume = "165",
pages = "450--455",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Disseminated herpes zoster in the immunocompromised host

T2 - A comparative trial of acyclovir and vidarabine

AU - Whitley, Richard J.

AU - Gnann, John W.

AU - Hinthorn, Daniel

AU - Liu, Chein

AU - Pollard, Richard B

AU - Hayden, Frederick

AU - Mertz, Gregory J.

AU - Oxman, Michael

AU - Soong, Seng Jaw

PY - 1992/3

Y1 - 1992/3

N2 - Seventy-three immunocompromised patients with disseminated herpes zoster were evaluated in a double-blind controlled trial of acyclovir (n = 37) versus vidarabine (n = 36) therapy. Acyclovir was administered at 30 mg/kg/day at 8-h intervals and vidarabine was given as a continuous 12-h infusion at 10 mg/kg/day for 7 days (longer if resolution of cutaneous or visceral disease was incomplete). No demographic differences existed between treatment groups. No deaths attributable to varicella-zoster virus infection occurred within 1 month of treatment. Neither rates of cutaneous healing, resolution of acute neuritis, and frequency of postherpetic neuralgia nor adverse clinical and laboratory events differed between treatment groups. Acyclovir recipients were discharged from the hospital more promptly than vidarabine recipients (P = .04, log rank test). These data indicate that disseminated herpes zoster is amenable to therapy with either acyclovir or vidarabine; resultant mortality is low.

AB - Seventy-three immunocompromised patients with disseminated herpes zoster were evaluated in a double-blind controlled trial of acyclovir (n = 37) versus vidarabine (n = 36) therapy. Acyclovir was administered at 30 mg/kg/day at 8-h intervals and vidarabine was given as a continuous 12-h infusion at 10 mg/kg/day for 7 days (longer if resolution of cutaneous or visceral disease was incomplete). No demographic differences existed between treatment groups. No deaths attributable to varicella-zoster virus infection occurred within 1 month of treatment. Neither rates of cutaneous healing, resolution of acute neuritis, and frequency of postherpetic neuralgia nor adverse clinical and laboratory events differed between treatment groups. Acyclovir recipients were discharged from the hospital more promptly than vidarabine recipients (P = .04, log rank test). These data indicate that disseminated herpes zoster is amenable to therapy with either acyclovir or vidarabine; resultant mortality is low.

UR - http://www.scopus.com/inward/record.url?scp=0026504576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026504576&partnerID=8YFLogxK

M3 - Article

VL - 165

SP - 450

EP - 455

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -